The cost-effectiveness of the SPHERE intervention for the secondary prevention of coronary heart disease
about
Multilevel models for cost-effectiveness analyses that use cluster randomised trial data: An approach to model choice.Cost effectiveness of group follow-up after structured education for type 1 diabetes: a cluster randomised controlled trial.Quality of reporting of complex healthcare interventions and applicability of the CReDECI list - a survey of publications indexed in PubMed.Multivariate Meta-Analysis of Preference-Based Quality of Life Values in Coronary Heart Disease.Six-year follow-up of the SPHERE RCT: secondary prevention of heart disease in general practiceTranslating policy into practice: a case study in the secondary prevention of coronary heart disease.The cost-effectiveness of a structured education pulmonary rehabilitation programme for chronic obstructive pulmonary disease in primary care: the PRINCE cluster randomised trial.Systematic review of model-based analyses reporting the cost-effectiveness and cost-utility of cardiovascular disease management programs.Economic implications of cardiovascular disease management programs: moving beyond one-off experiments.A comparison of medical records and patient questionnaires as sources for the estimation of costs within research studies and the implications for economic evaluation.Long-term cost effectiveness of cardiac secondary prevention in primary care in the Republic of Ireland and Northern Ireland.Comparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe, using the FRAX algorithm.Modelling coronary heart disease mortality in Northern Ireland between 1987 and 2007: broader lessons for prevention.Relative cost effectiveness of the SPHERE intervention in selected patient subgroups with existing coronary heart disease
P2860
Q30717228-80AD39B8-DD22-48D5-9138-7D131491FF19Q33803366-2E4B7BF2-3864-4880-8818-29C886709067Q35020399-51530279-66EF-47B2-B370-D4AE03651469Q35969302-6244D92E-651A-4F2D-B9D4-3C4B32A9F9A1Q36258628-D11E8BEC-4F54-4023-94AD-8DAE942B9B43Q37333071-B06BAB57-D1F3-435C-980C-64B61C0432B5Q37353356-74AFF361-BE01-481A-BF1A-33465C61496FQ38212439-8392FD63-6D3E-4D95-9123-CBA73B8EBE36Q38479575-3D67E9A6-D0A8-4CAE-8F3F-66D058F0B3E2Q39429605-4C6A62EF-AC2D-4251-95A9-085166D26215Q39933575-26D694A2-8863-4DA1-9325-F5FB925236E5Q48154405-5A6D2CF7-B104-4EF7-9464-D6AD01540D16Q53647413-64D64AD8-61A4-4A63-BF31-DD0C0DBEC3DAQ57589928-C13FEF7B-B3F5-4D4A-AD34-1A3BA9BB73BA
P2860
The cost-effectiveness of the SPHERE intervention for the secondary prevention of coronary heart disease
description
im Juli 2010 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 July 2010
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в червні 2010
@uk
name
The cost-effectiveness of the ...... tion of coronary heart disease
@en
The cost-effectiveness of the ...... tion of coronary heart disease
@nl
type
label
The cost-effectiveness of the ...... tion of coronary heart disease
@en
The cost-effectiveness of the ...... tion of coronary heart disease
@nl
prefLabel
The cost-effectiveness of the ...... tion of coronary heart disease
@en
The cost-effectiveness of the ...... tion of coronary heart disease
@nl
P2093
P2860
P50
P1476
The cost-effectiveness of the ...... tion of coronary heart disease
@en
P2093
Andrew W Murphy
Eamon O'Shea
Mary C Byrne
Molly Byrne
P2860
P304
P356
10.1017/S0266462310000358
P577
2010-07-01T00:00:00Z